Adapting Traditional Drug Development Methods for Epigenetic Therapies- Peter Staller
Peter Staller Director of Oncology Research at Epitherapeutics talks to Pharma IQ about the differences between traditional drug development techniques and those required for development of a epigenetic therapy. He also discusses epigenetics as a growing area for finding druggable targets and the maturity of the field.
Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue reading this story
Please note: That all fields marked with an asterisk (*) are required.